Search

Meet Antonio Almeida, our February Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Meet Antonio Almeida, our February Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

EHA & ERN-EuroBloodNet Spotlight on Hypereosinophilic Syndrome Webinars

An accredited European online educational program for health professionals, organized by EHA and ERN-EuroBloodNet. DatesThe sessions will take place on :

Monday, April 15, 2024 at 17:00 (CEST). Monday, May 13, 2024 at 17:00 (CEST).

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more

Congress Sponsor Program

Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.

Read more